Payment overview · 2025
General Payments
$1,544.69
95 reported records · 19 companies
Healthcare provider profile · identity verified
William A Gammill, DO
Allopathic & Osteopathic Physicians|Pediatrics · ENTERPRISE, AL · NPI 1437199908
Verified facts
What the public records show
CMS Open Payments records show William A Gammill, DO received $1,544.69 in general payments during 2025 across 95 reported records.
Axsome Therapeutics, Inc. accounted for 15.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 305 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $245.37 | 15.9% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $208.82 | 13.5% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $193.56 | 12.5% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $183.57 | 11.9% | 19 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $154.62 | 10.0% | 13 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $135.70 | 8.8% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $76.15 | 4.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $66.06 | 4.3% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $53.66 | 3.5% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $40.24 | 2.6% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $28.73 | 1.9% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $26.49 | 1.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.83 | 1.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.41 | 1.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.77 | 1.4% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.15 | 1.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.06 | 1.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.36 | 1.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.14 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,544.69 | 95 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $213.38 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $193.56 | 12 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $193.56 | 12 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $157.47 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $112.02 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $109.38 | 13 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $106.96 | 7 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $101.86 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $76.15 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $70.35 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $70.33 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $62.21 | 5 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $40.24 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $38.65 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $36.69 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $36.69 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $34.85 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.06 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $31.99 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.37 | 2 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $28.73 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $26.49 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.83 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.41 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $11.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 305 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 159 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 79 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 110 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
17 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
110 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
305 | 59 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
159 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
163 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
79 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
156 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 648 | 153 |
| Atorvastatin Calcium | Atorvastatin Calcium | 569 | 145 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 494 | 64 |
| Omeprazole | Omeprazole | 487 | 131 |
| Lisinopril | Lisinopril | 458 | 118 |
| Pantoprazole Sodium | Pantoprazole Sodium | 435 | 119 |
| Gabapentin | Gabapentin | 433 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 423 | 114 |
| Tramadol Hcl | Tramadol Hcl | 398 | 74 |
| Meloxicam | Meloxicam | 379 | 100 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 375 | 104 |
| Metformin Hcl | Metformin Hcl | 365 | 106 |
| Losartan Potassium | Losartan Potassium | 344 | 98 |
| Jardiance | Empagliflozin | 305 | 59 |
| Alprazolam | Alprazolam | 299 | 45 |
| Trazodone Hcl | Trazodone Hcl | 283 | 67 |
| Furosemide | Furosemide | 256 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 228 | 63 |
| Zolpidem Tartrate | Zolpidem Tartrate | 222 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 202 | 56 |
| Simvastatin | Simvastatin | 193 | 50 |
| Valsartan | Valsartan | 192 | 43 |
| Sertraline Hcl | Sertraline Hcl | 185 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 176 | 53 |
| Potassium Chloride | Potassium Chloride | 164 | 51 |
| Trulicity | Dulaglutide | 163 | 23 |
| Mounjaro | Tirzepatide | 159 | 24 |
| Temazepam | Temazepam | 158 | 20 |
| Eliquis | Apixaban | 156 | 30 |
| Clonazepam | Clonazepam | 142 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 131 | 39 |
| Carvedilol | Carvedilol | 131 | 36 |
| Fenofibrate | Fenofibrate | 128 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 127 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 125 | 34 |
| Montelukast Sodium | Montelukast Sodium | 125 | 37 |
| Estradiol | Estradiol | 124 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 123 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 118 | 36 |
| Xarelto | Rivaroxaban | 118 | 21 |
| Prednisone | Prednisone | 111 | 61 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 110 | 22 |
| Famotidine | Famotidine | 107 | 27 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 107 | 85 |
| Fluoxetine Hcl | Fluoxetine Hcl | 103 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 32 |
| Allopurinol | Allopurinol | 101 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 98 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 97 | 15 |
| Pregabalin | Pregabalin | 95 | 16 |
| Ezetimibe | Ezetimibe | 94 | 22 |
| Memantine Hcl | Memantine Hcl | 92 | 22 |
| Lorazepam | Lorazepam | 91 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 89 | 17 |
| Donepezil Hcl | Donepezil Hcl | 82 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 82 | 22 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 81 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 81 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 79 | suppressed |
| Ozempic | Semaglutide | 79 | 14 |
| Celecoxib | Celecoxib | 78 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 23 |
| Azithromycin | Azithromycin | 74 | 64 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 72 | 22 |
| Buspirone Hcl | Buspirone Hcl | 68 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 66 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 13 |
| Glimepiride | Glimepiride | 64 | 17 |
| Myrbetriq | Mirabegron | 63 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 62 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 62 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 20 |
| Fluconazole | Fluconazole | 59 | 23 |
| Linzess | Linaclotide | 58 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 58 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 55 | 16 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 55 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 54 | 18 |
| Spironolactone | Spironolactone | 54 | 15 |
| Bupropion Xl | Bupropion Hcl | 53 | 15 |
| Promethazine Hcl | Promethazine Hcl | 53 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 51 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 40 |
| Finasteride | Finasteride | 49 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 15 |
| Metformin Hcl Er | Metformin Hcl | 45 | 14 |
| Methadone Hcl | Methadone Hcl | 45 | suppressed |
| Baclofen | Baclofen | 44 | suppressed |
| Methocarbamol | Methocarbamol | 44 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 44 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 44 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 13 |
| Eszopiclone | Eszopiclone | 40 | suppressed |
| Fentanyl | Fentanyl | 39 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 39 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 35 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 15 |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | 12 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 37 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 37 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 12 |
| Entresto | Sacubitril/Valsartan | 35 | suppressed |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 34 | suppressed |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Cilostazol | Cilostazol | 33 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 32 | suppressed |
| Mirtazapine | Mirtazapine | 31 | 14 |
| Oxcarbazepine | Oxcarbazepine | 31 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 31 | suppressed |
| Vraylar | Cariprazine Hcl | 31 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 30 | suppressed |
| Verapamil Er | Verapamil Hcl | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Nystatin | Nystatin | 28 | 18 |
| Pitavastatin Calcium | Pitavastatin Calcium | 28 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Belsomra | Suvorexant | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 23 | 23 |
| Diltiazem 24hr Er | Diltiazem Hcl | 23 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 14 |
| Carisoprodol | Carisoprodol | 21 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 21 | suppressed |
| Invokana | Canagliflozin | 21 | suppressed |
| Livalo | Pitavastatin Calcium | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 18 |
| Nyamyc | Nystatin | 19 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Etodolac | Etodolac | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 17 | 15 |
| Sucralfate | Sucralfate | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Misoprostol | Misoprostol | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 13 |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Verquvo | Vericiguat | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | 13 |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Victoza 3-Pak | Liraglutide | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Fml Forte | Fluorometholone | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 12 |
| Imipramine Pamoate | Imipramine Pamoate | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,544.69 · 95 records | Axsome Therapeutics, Inc. | AIRSUPRA, Auvelity, Azstarys, CAPLYTA, Cologuard Collection Kit, EVENITY, FARXIGA, Flucelvax, GEMTESA, INSPIRE, JARDIANCE, KISUNLA, Kerendia, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, Symbravo, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error